Trekrezan in 130 adults with acute respiratory viral infections
Comparison in people · 2021
- What was studied
- 130 adults with mild-to-moderate acute respiratory viral infection. Trekrezan: 100. Symptomatic-care comparison: 30. SARS-CoV-2-positive patients were excluded.
- Main finding
- In an open comparison of 130 adults, respiratory symptoms resolved an average of 2.2 days sooner in the Trekrezan group.
Reported findings and study design
Prospective, open-label postmarketing comparison of Trekrezan plus symptomatic care with symptomatic care alone.
Population or model 130 adults with mild-to-moderate acute respiratory viral infection. Trekrezan: 100. Symptomatic-care comparison: 30. SARS-CoV-2-positive patients were excluded.
Dose, route and schedule
Oral Trekrezan 600 mg on day 1, then 200 mg/day for seven days (2,000 mg total). Symptomatic medication was available to both groups as needed.
Protocol source ↗ · Original journal article, treatment groups, dosing and results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Resolution of acute respiratory symptoms | 2.2 days sooner on average with Trekrezan | p<0.05 |
| Fever | Resolved sooner in the Trekrezan group | p=0.03 |
| C-reactive protein | The between-group comparison did not show a significant difference in the subgroup assessed. |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- Open observational design with unequal groups and symptom-based outcomes. The 2023 Esaulenko paper reused the 30 adult controls.
Related publications may describe some of the same participants or experiments.
Source details
Original journal article, treatment groups, dosing and results.
Sources checked
Citation
Y. V. Frolova, N. M. Golanova, D. G. Listradenkova, E. P. Amon, E. Y. Malinnikova. Trekrezan in 130 adults with acute respiratory viral infections Therapy. 2021;7(8):172–181.
Study source ↗ · DOI 10.18565/therapy.2021.8.172-181 · Bibliography entry · Link to this summary